Special issue of the journal titled: Drug delivery for specific population
C.03 Guest-associated editor
Professional monograph
F.17 Transfer of existing technologies, know-how, methods and procedures into practice
COBISS.SI-ID: 281719808The main goal of the analytical part of the project was determination of qualitative and quantitative presence of pharmaceutical contaminants in wastewater samples from retirement homes and hospitals. Simultaneously, we upgraded the extraction and analytical methods for detection of pharmaceuticals and their metabolites in low concentration range which included the automated SPE-DEX technique (Horizon Technology) as the most suitable sample preparation method. It enables fast, automated and consecutive filtration and extraction. The optimised method was applied to wastewater samples from eight different sources; furthermore, three sampling events per day have been performed at the institutions deemed most suitable for setting up a pilot wastewater treatment plant. The results have shown the presence of several pharmaceuticals in wastewater samples; among the treated analytes, five compounds, bisoprolol, metoprolol, carbamazepine, ciprofloxacin and diclofenac were detected in all samples in the highest concentration: 2,8 µg/L, 2,9 µg/L, 1,4 µg/L, 149 µg/L, 4,5 µg/L, respectively. The rest of studied pharmaceuticals were detected less frequently, while clofibric acid, imatinib and simazine were not detected in any of the tested samples. According to the preliminary results, the re-evaluation of the selected analytes was done; clofibric acid and fluoxetine were substituted by atorvastatin and sertraline, whereas both pesticides (atrazine and simazine) were excluded. Additionally, on the finally selected site for setting up a treatment plant, further studies are planned in order to optimize the selection of monitored pharmaceuticals as well as further optimization of the analytical method.
F.09 Development of a new technological process or technology
COBISS.SI-ID: 3893617The knowledge obtained by studying the physiological basis of the dosage forms performance after oral administration enables us the collaboration with pharmaceutical industry in different projects on generic dosage forms development. We develop models for drug release evaluation, and on the basis of good knowledge of certain drug and dosage form critical parameters for developing dosage forms are anticipated, the most biorelevant system for dosage form evaluation is projected and dosage form’s performance after administration predicted. Thus we collaborate in the selection of the dosage form and contribute significantly to increase of successfulness of bioequivalence studies.
F.09 Development of a new technological process or technology
Drugs imatinib, raloxifene and remifentanil are specific cases as they demand individualized dosing on the basis of therapeutic drug monitoring and evaluation of polimorphism of genes coding for drug metabolizing enymes and transporters.
B.04 Guest lecture
COBISS.SI-ID: 3925361